Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Ripretinib

INTRIGUE

Deciphera Pharmaceuticals · Phase 3 · Active, not recruiting · Enrollment 453

NCT03673501

Catalyst Primary completion. 09.01.2021. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety
Ripretinib 150 mggrade 3 or 4 treatment-emergent adverse events: 41.3%, primary analysis
Sunitinib 50 mg 4/2grade 3 or 4 treatment-emergent adverse events: 65.6%, primary analysis

A count stays a count. This page does not turn a count into a percent.